Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection - IMI2-2018-16-03

Deadline: Oct 24, 2018  
CALL EXPIRED

The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipeline of treatments and preventions for AMR infections by enabling vibrant and nimble collaborations between EFPIA companies and small and medium-sized enterprises (SMEs) and/or academics that will advance the R&D pipeline of new and innovative agents to address AMR.

Novel assets with new mechanisms of action will be identified through high throughput screening campaigns for tuberculosis (TB) and non-tubercular mycobacteria (NTM), with a special focus on M. avium complex. Novel screening platforms and tools are needed for this evaluation. The resulting hits will be profiled and further optimised in vitro and in vivo. In addition, a better understanding of the host-mycobacteria interaction and the impact of coexisting viral infections can provide insights about biomarkers and new targets for mycobacteria.

The expected impact of actions selected under this Call will be to: (1) contribute to the development of a vibrant AMR research environment in the EU and strengthen the competitiveness and industrial leadership of Europe; (2) contribute to the EU’s ambition of being a ‘best practice region’ for addressing AMR; (3) enhance the overall pipeline of medicines for patients with AMR infections and advance new and innovative agents.